Could a common diabetes drug shield your brain after a stroke?
NCT ID NCT07241897
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a diabetes drug called sentagliptin (a DPP4 inhibitor) can improve thinking and memory in people who have had a mild stroke and also have type 2 diabetes. About 312 participants will receive either the drug or a placebo daily for 180 days. Researchers will measure changes in cognitive tests to see if the drug reduces the risk of post-stroke cognitive impairment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sentagliptin Phosphate (a DPP4 inhibitor diabetes drug)
What this could lead to
If it works, this could point toward a new way to protect brain function after a stroke in people with diabetes.
What could go wrong
This is a Phase 3 trial, but it hasn't started yet. The drug may not improve cognition, and side effects from the medication are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Neurology, Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215004, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••